Epigenetic Regulation of Immunecells in patients with SARS-CoV2 (COVID-19)

Epigenetic Regulation of Immunecells in patients with SARS-CoV2 (COVID-19) - EpICoV

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024378

Enrollment

Registered

2021-02-02

Start date

2020-12-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19

Interventions

Group 1: Analysis of Chromatin variations via ChIP and NGS (next Generation sequenzing), Analysis of transcriptome and metabolome at the time of Admission (day 1) as well as days 8 and 30.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: infection with COVID-19

Exclusion criteria

Exclusion criteria: infection with HIV or viral hepatitis

Design outcomes

Primary

Measure	Time frame
Analysis of Chromatin variations via ChIP and NGS (next Generation sequenzing), Analysis of transcriptome and metabolome	—

Secondary

Measure	Time frame
Immunephenotyping via FACS	—

Countries

Germany

Contacts

Public ContactMarkus Alexander Weigand

Klinik für Anästhesiologie Universitätsklinikum Heidelberg

markus.weigand@med.uni-heidelberg.de06221 56-6350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026